FemPulse Corporation

FemPulse Corporation is a disruptive healthcare startup dedicated to revolutionizing women's health with its cutting-edge bioelectronic medicine technology. Tackling the widespread issue of overactive bladder (OAB) that affects over 15 million women in the US, the company aims to provide a non-invasive, user-friendly solution to this debilitating condition. The current treatments for OAB, including medication, surgery, and invasive procedures, often deter patients from seeking proper care, significantly impacting their quality of life. Acknowledging the drawbacks of existing neuromodulation therapy for OAB, FemPulse has developed a novel, wearable medical device delivering targeted neuromodulation therapy directly to the bladder-regulating nerves. This approach bypasses the need for surgical implant, offering a more accessible and convenient alternative for patients. The device's user-friendly design allows for self-placement and control through a smartphone app, enhancing its appeal and usability. FemPulse Corporation, founded in 2011, operates in the Consumer Goods and Manufacturing industries and is currently undergoing clinical evaluations in the United States. The company's innovative approach to addressing a prevalent health issue, coupled with its focus on user convenience and accessibility, positions it as a promising venture for potential investors interested in the healthcare and medical device sectors.